Lupin intends to commercialise the anti-tuberculosis (TB) medicine in approximately 140 countries and territories, including many of the highest TB burden countries around the world
TB Alliance has granted global pharma major Lupin, a non-exclusive license to manufacture the anti-TB drug pretomanid as part of the three-drug “BPaL” regimen. Lupin intends to commercialise the anti-tuberculosis (TB) medicine in approximately 140 countries and territories, including many of the highest TB burden countries around the world.
Mel Spigelman, President and CEO, TB Alliance said, “TB Alliance is committed to ensure its products are widely available and affordable to those who need them. Partnering with Lupin, a well-established manufacturer with experience delivering high quality TB therapies, will help further enable widespread access to our novel regimen while promoting a competitive market to drive affordability.”
Nilesh Gupta, Managing Director, Lupin added, “As a global leader in anti-TB medicines, Lupin is committed to enhancing access to bridge unmet needs in countries where it is needed the most. This collaboration with TB Alliance leverages our strength and expertise to contribute to better global health.”
Naresh Gupta, President API Plus, Lupin said, “Tuberculosis is one of humanity’s oldest, deadliest, and most persistent diseases. Lupin is the largest supplier of first-line anti-TB drugs in the world, and we are excited to partner with TB Alliance to help bring new therapies for highly drug-resistant TB to reach individuals and countries where access to these medicines is so urgently needed.”